Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

OP25: Lymphocytic colitis can be transcriptionally divided into channelopathic and inflammatory lymphocytic colitisECCO'25 Berlin
Year: 2025
Authors: Escudero-Hernández, Celia
OP26: Disentangling the role of HLA proteins in shaping the T-cell repertoire in Inflammatory Bowel Disease using CDR3-QTL analysisECCO'25 Berlin
Year: 2025
Authors: Lokes, Evgeniya
OP27: Unlocking Inflammatory Bowel Disease subtypes: a deep dive into transcriptomics and Machine LearningECCO'25 Berlin
Year: 2025
Authors: Acharjee, Animesh
OP28: Anti-integrin αvβ6 autoantibodies are detected in preclinical, incident and established colonic Crohn’s diseaseECCO'25 Berlin
Year: 2025
Authors: Livanos, Alexandra
OP29: Breaking New Ground in IBD Research: Organoid Models as the Vanguard for Personalized TherapiesECCO'25 Berlin
Year: 2025
Authors: Verstockt, Bram
OP30: Dissecting the genetic basis of clinical phenotype heterogeneity within IBD in more than 63,000 IBD patientsECCO'25 Berlin
Year: 2025
Authors: McGovern, Dermot
OP31: Phase 1b study of SOR102, a novel, orally delivered bispecific anti-TNF/anti-IL-23 domain antibody in patients with mild to severe ulcerative colitisECCO'25 Berlin
Year: 2025
Authors: Jairath, Vipul
OP32: Identifying clusters of antibiotic use patterns after the first episode of pouchitis in a population-based cohortECCO'25 Berlin
Year: 2025
Authors: Barnes, Edward
OP33: Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: Results through Week 48 from the phase 3 GRAVITI studyECCO'25 Berlin
Year: 2025
Authors: Hart, Ailsa
OP34: Mirikizumab demonstrates rapid improvements in bowel urgency severity, bowel urgency frequency, and stool deferral time in patients with moderately-to-severely active Ulcerative Colitis: 12-week interim results from the phase 3b LUCENT-URGE trialECCO'25 Berlin
Year: 2025
Authors: Danese, Silvio
OP35: Low remission recapture after ustekinumab dose optimization in Crohn’s disease: results of the randomized placebo-controlled double-blind REScUE study.ECCO'25 Berlin
Year: 2025
Authors: Bossuyt, Peter
OP36: Lusvertikimab, a first-in-class IL7 receptor antagonist, in moderate to severe Ulcerative Colitis: results of a multicenter, randomized, placebo-controlled phase II studyECCO'25 Berlin
Year: 2025
Authors: Bourreille, Arnaud
OP37: Delineating molecular and microbial signatures across disease severity in Inflammatory Bowel Disease in adult treatment naive patients through single-cell transcriptomic and microbiome profiling.ECCO'25 Berlin
Year: 2025
Authors: Leipner, Matthew
OP38: Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in patients with ulcerative colitis: a double-blind randomized controlled trial (EFFICACI)ECCO'25 Berlin
Year: 2025
Authors: Bouguen, Guillaume
OP39: Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active ulcerative colitis – Results from TUSCANY-2ECCO'25 Berlin
Year: 2025
Authors: Jairath, Vipul
OP40: Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn’s disease: results from a phase 2b, randomised, double-blind, placebo-controlled dose-ranging, basket trial (RELIEVE UCCD)ECCO'25 Berlin
Year: 2025
Authors: Jairath, Vipul
OP41: Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: Results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD)ECCO'25 Berlin
Year: 2025
Authors: Reinisch, Walter
SCI01: OpeningECCO'25 Berlin
Year: 2025
Authors: Siegmund, Britta
SCI02: Novel strategies to achieve a sustainable treatmentECCO'25 Berlin
Year: 2025
Authors: Louis, Edouard
SCI03: Impact of lifestyle to sustain health and prevent IBDECCO'25 Berlin
Year: 2025
Authors: Banerjee, Rupa